Falcon Peps / Research journal
Clinical trials, laboratory findings and the questions that matter. Follow the evidence from mechanism to meaningful outcomes.
A source-led review of retatrutide’s 2026 trial programme, separating published results, sponsor announcements and unresolved questions.
Read the research : Retatrutide in 2026: reading the TRIUMPH evidence16 articles · Primary sources linked
A seven-residue fragment, full-length thymosin beta-4 and a recombinant study product are not interchangeable. Their human research must be read separately.
Read the research : Thymosin beta-4 and TB-500: identity changes the evidenceIdentity, purity, quantity, sterility and endotoxin results answer different questions. Learn what an analytical report can establish—and what remains untested.
Read the research : Peptide quality: why HPLC purity is only one measurementA practical guide to trial phases, endpoints, estimands and effect sizes—and the questions that separate a useful result from an oversized claim.
Read the research : How to read a peptide trial without overreading the resultThe research is not all at the same level. A close reading of cell experiments, rat studies and small human reports shows where the evidence stops.
Read the research : BPC-157: what laboratory, animal and human studies showA careful reading of the Phase 2a hair-density signal, safety claims and October 2026 AWAKEN trial announcement.
Read the research : PP405 hair research: early results and the next trialA closer look at cell and animal findings alongside small human studies of specific topical formulations, skin outcomes and wound repair.
Read the research : GHK-Cu for skin and wounds: what the evidence supportsThe motor-function results, current US approval and safety context—and why SMA findings cannot be converted into healthy-adult performance claims.
Read the research : Apitegromab after SAPPHIRE: what the SMA evidence meansFive human trials show why weight change, diabetes incidence, maintenance and heart-failure events need separate interpretations.
Read the research : Tirzepatide evidence: beyond the weight-loss headlineNew phase 3 trials expand survodutide research, but weight loss, liver-fat imaging and biopsy outcomes answer different questions.
Read the research : Survodutide: obesity and liver evidence in 2026Falcon Peps publishes source-linked research summaries covering peptides and related drug development. Human trials, laboratory work and company announcements are labelled separately.
Each article links to original sources and explains the study design, findings and open questions. Evidence review dates show when those sources were last checked.
Archive dates refer to earlier research milestones. The actual publication and evidence-review dates remain visible on each article. To flag an error, quote the article and source when contacting Falcon Peps.
The entry notice could not load. Reload the page to continue.
